Human Coagulation Factor VIII Market Trends Top 5 Insights Shaping the Industry
According to a new report from Intel Market Research , global Human Coagulation Factor VIII market was valued at USD 9980 million in 2025 and is projected to reach USD 15670 million by 2032 , exhibiting a CAGR of 6.8% throughout the forecast period (2025–2032). This steady growth trajectory is propelled by several interconnected factors, including the rising global prevalence of Hemophilia A, increased demand for advanced recombinant therapies, and significant improvements in healthcare infrastructure, particularly within emerging economies. The market's expansion is fundamentally driven by the critical, lifelong need for effective treatments to manage this chronic bleeding disorder effectively. What is Human Coagulation Factor VIII? Human Coagulation Factor VIII is an essential blood-clotting protein, also known clinically as anti-hemophilic factor (AHF). It is encoded by the F8 gene in humans, and genetic defects within this gene are the direct cause of Hemophilia A, ...